Posted by Michael Wonder on 26 Nov 2019
Phathom Pharmaceuticals provides corporate update
25 November 2019 - Received qualified infection disease pathogen designation from the U.S. FDA for vonoprazan in combination with both amoxicillin and clarithromycin and in combination with amoxicillin alone for the treatment of H. pylori infection.
With the designation, Phathom’s H. pylori program is eligible for certain benefits, including potential eligibility for priority review.
